Related Experiment Video
Updated: Jun 16, 2026
08:44
Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models
Published on: November 11, 2014
Applying Hsp104 to protein-misfolding disorders
Shilpa Vashist1, Mimi Cushman, James Shorter
1Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, 805b Stellar-Chance Laboratories, 422 Curie Boulevard, Philadelphia, PA 19104, USA.
Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire
|February 5, 2010
Summary
Heat shock protein 104 (Hsp104) resolves protein aggregates. This chaperone shows therapeutic potential by inhibiting alpha-synuclein in Parkinson's disease models, but not amyloid-beta in Alzheimer's disease models.
Area of Science:
- Molecular Biology
- Neuroscience
- Biochemistry
Background:
- Hsp104, a yeast AAA+ ATPase, disaggregates proteins and remodels amyloids, aiding stress survival and prion-based adaptation.
- Metazoa lack direct Hsp104 orthologues, suggesting a gap in coupled protein disaggregation and renaturation systems.
- Protein misfolding and aggregation into amyloids underlie neurodegenerative diseases like Alzheimer's and Parkinson's.
Purpose of the Study:
- To review the potential of applying yeast Hsp104 to metazoan proteostasis, specifically targeting protein-misfolding diseases.
- To evaluate Hsp104's efficacy against amyloid-beta (Abeta42) in Alzheimer's disease and alpha-synuclein in Parkinson's disease.
Main Methods:
- Review of existing literature on Hsp104 function and its application in neurodegenerative disease models.
- Assessment of Hsp104's effects on Abeta42 amyloidogenesis and preformed fibers.
- Evaluation of Hsp104's impact on alpha-synuclein oligomer/fiber formation and related neurodegeneration in rat models.
Main Results:
- Hsp104 potently inhibits Abeta42 amyloidogenesis but cannot disaggregate preformed Abeta42 fibers.
- Hsp104 effectively inhibits and reverses alpha-synuclein oligomer and fiber formation.
- Hsp104 antagonizes alpha-synuclein-induced dopaminergic neuron degeneration in a rat model.
Conclusions:
- Hsp104 demonstrates therapeutic promise for Parkinson's disease by targeting alpha-synuclein.
- Hsp104's inability to disaggregate preformed Abeta42 fibers limits its application for Alzheimer's disease.
- Further research into Hsp104-based strategies may offer novel treatments for protein-misfolding neurodegenerative disorders.
Related Concept Videos
03:00Molecular Chaperones and Protein Folding
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
03:00Molecular Chaperones and Protein Folding
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
01:32Export of Misfolded Proteins out of the ER
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:37The Unfolded Protein Response
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
01:26Bacterial Protein Maturation
Bacterial protein maturation is a tightly regulated process that ensures newly synthesized polypeptides achieve correct functional conformations. This maturation involves a series of modifications, folding events, and quality control steps, often assisted by specialized chaperone proteins.N-Terminal ModificationsThe maturation of bacterial polypeptides begins cotranslationally as the polypeptide exits the ribosome. The first amino acid, N-formylmethionine (fMet), is typically modified at the...